Compugen Appoints Michelle Mahler, M.D. as Chief Medical Officer
Ticker: CGEN · Form: 6-K · Filed: Feb 15, 2024 · CIK: 1119774
| Field | Detail |
|---|---|
| Company | Compugen Ltd (CGEN) |
| Form Type | 6-K |
| Filed Date | Feb 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: executive-change, appointment, biotechnology
TL;DR
**Compugen just hired Michelle Mahler, M.D. as their new Chief Medical Officer, effective March 1, 2024, signaling a focus on clinical development.**
AI Summary
Compugen Ltd. announced on February 15, 2024, the appointment of Michelle Mahler, M.D., as its new Chief Medical Officer. Her appointment is effective March 1, 2024. This strategic hire aims to strengthen the company's clinical development capabilities and leadership.
Why It Matters
The appointment of a Chief Medical Officer is crucial for a biotechnology company like Compugen, as this role typically oversees clinical trials and regulatory strategy, directly impacting the progression of its drug candidates.
Risk Assessment
Risk Level: low — This filing reports a standard executive appointment, which is an operational change and does not inherently introduce significant financial or operational risk.
Key Players & Entities
- Compugen Ltd. (company) — registrant
- Michelle Mahler, M.D. (person) — Chief Medical Officer
- Anat C (person) — quoted in press release
FAQ
Who did Compugen Ltd. appoint as Chief Medical Officer?
Compugen Ltd. appointed Michelle Mahler, M.D. as Chief Medical Officer.
When is Michelle Mahler, M.D.'s appointment as Chief Medical Officer effective?
Her appointment is effective March 1, 2024.
What is the name of the company making this appointment?
The company making this appointment is Compugen Ltd.
On what date did Compugen Ltd. issue the press release announcing this appointment?
Compugen Ltd. issued the press release on February 15, 2024.
What type of SEC form is this filing?
This is a Form 6-K, a report of a foreign private issuer.
Filing Stats: 252 words · 1 min read · ~1 pages · Grade level 9 · Accepted 2024-02-15 07:00:08
Filing Documents
- zk2430998.htm (6-K) — 12KB
- exhibit_99-1.htm (EX-99.1) — 10KB
- image00001.jpg (GRAPHIC) — 5KB
- 0001178913-24-000605.txt ( ) — 30KB
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. COMPUGEN LTD. Date: February 15, 2024 By: /s/ Eran Ben Dor Eran Ben Dor General Counsel